Fatal Heart Failure Induced by Pazopanib in a Sarcoma Patient Previously Treated with Gemcitabine.
cardio-oncology
cardiotoxicity
gemcitabine
heart failure
pazopanib
Journal
Journal of the Saudi Heart Association
ISSN: 1016-7315
Titre abrégé: J Saudi Heart Assoc
Pays: Saudi Arabia
ID NLM: 9887261
Informations de publication
Date de publication:
2020
2020
Historique:
received:
18
04
2020
accepted:
10
06
2020
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
7
11
2020
Statut:
epublish
Résumé
Gemcitabine is commonly used for various solid organ malignancies with rarely reported cardiac side effects such as cardiomyopathy. Pazopanib usually can cause arterial hypertension but cases of heart failure have recently been reported. We describe a case of fatal heart failure after treatment with gemcitabine and pazopanib in a 55-year-old female with sarcoma. Patient developed left ventricular dysfunction after gemcitabine treatment and acute heart failure after 22 days of pazopanib treatment which led to death. Physicians should be aware of the cardiotoxicity risk when managing the use of pazopanib especially in patients previously treated with other cardiotoxic drugs.
Identifiants
pubmed: 33154930
doi: 10.37616/2212-5043.1125
pii: sha-32-02-285
pmc: PMC7640551
doi:
Types de publication
Case Reports
Langues
eng
Pagination
285-287Informations de copyright
© 2020 Saudi Heart Association.
Références
Expert Opin Drug Saf. 2015 Feb;14(2):253-67
pubmed: 25494575
Antioxid Redox Signal. 2019 Jun 20;30(18):2110-2153
pubmed: 28398124
Anticancer Res. 2014 Dec;34(12):7267-70
pubmed: 25503159
ESC Heart Fail. 2017 Feb;4(1):71-74
pubmed: 28217315
J Med Case Rep. 2014 Jun 23;8:220
pubmed: 24957905
Expert Opin Drug Saf. 2008 Nov;7(6):703-16
pubmed: 18983217
BMJ Case Rep. 2018 Aug 16;2018:
pubmed: 30115717
J Oncol Pharm Pract. 2020 Apr;26(3):768-774
pubmed: 31547750
Acta Oncol. 2017 Sep;56(9):1233-1234
pubmed: 28537442
Anticancer Drugs. 2006 Mar;17(3):359-61
pubmed: 16520666
Cancer Treat Rev. 2011 Jun;37(4):300-11
pubmed: 21126826